Mesa Laboratories (MLAB) CAO Elizabeth Buys $25K of Stock

Crennen Lyndsey Elizabeth, the Chief Accounting Officer (CAO) of Mesa Laboratories, Inc. (NasdaqGS: MLAB), recently acquired additional shares in the company. On June 18, 2026, she purchased 263 shares at an average price of $95.10 each, for a total transaction value of $25,011. This purchase was not part of a pre-planned trading program.

Other Institutional Activity in Mesa Laboratories

Institutional investors have shown varied interest in Mesa Laboratories. Long Path Partners LP significantly increased its holdings by 178,360 shares, bringing its total to 405,583 shares valued at approximately $35.9 million, reflecting a 78.5% increase. Boston Partners also grew its stake, adding 55,335 shares to reach a total of 268,711 shares worth around $23.8 million, marking a 25.9% increase. Meanwhile, BlackRock, Inc. slightly reduced its position by 4,815 shares, now holding 393,851 shares valued at $34.8 million, a 1.2% decrease. Select Equity Group, L.P. increased its holdings by 29,450 shares to 235,885 shares, valued at $20.9 million, a 14.3% increase. Vanguard Capital Management LLC opened a new position with 232,643 shares valued at $20.6 million.

Mesa Laboratories, Inc. Stock Down 26.3%

Shares of Mesa Laboratories, Inc. traded near $93.23 on Tuesday. The company, which operates in the technology sector, specifically in scientific and technical instruments, has a market capitalization of $515.1 million. Its P/E ratio stands at 77.05, with a forward P/E of 7.60, and it has a beta of 0.927. Over the past 52 weeks, the stock has ranged from a low of $55.45 to a high of $113.99. The stock's 50-day moving average is $101.99, and its 200-day moving average is $84.97. Mesa Laboratories maintains a current ratio of 1.717 and a quick ratio of 1.174, with a debt-to-equity ratio of 90.65.

Recent Earnings

In its recent earnings report, Mesa Laboratories posted revenue of $249.1 million, reflecting a growth rate of 2.6%. The company's earnings per share (EPS) was reported at $1.21. Mesa Laboratories achieved a net margin of 2.69% and a return on equity (ROE) of 3.88%. The next earnings release is scheduled for August 5, 2026.

Dividend

Mesa Laboratories pays an annual dividend of $0.64 per share, yielding 0.67%. The company's dividend payout ratio is 52.89%.

Insider Buying and Selling at Mesa Laboratories, Inc.

On June 18, 2026, in addition to Crennen Lyndsey Elizabeth's purchase, CFO John Sakys also bought 2,282 shares at $95.10 each. On the same day, SVP Operations Brian David Archbold acquired 1,859 shares at the same price. Following these transactions, on June 22, 2026, Crennen Lyndsey Elizabeth, John Sakys, and Brian David Archbold sold shares at $89.50 each.

Analysts Set New Price Targets

Analyst activity around Mesa Laboratories includes Wells Fargo maintaining a "hold" rating with a $94.00 price target as of February 4, 2026. The consensus among analysts is a mean price target of $112.00, based on two opinions.

About Mesa Laboratories

Mesa Laboratories, Inc. is a technology company based in Lakewood, Colorado. It designs and manufactures life sciences tools and quality control products. The company's offerings include sterilization and disinfection control, clinical genomics with genetic analysis tools, biopharmaceutical development systems, and calibration solutions for various industries. Mesa Laboratories operates globally, serving sectors like pharmaceuticals and healthcare, and is led by CEO Dr. Siddhartha Chandrakant Kadia.

Bottom Line

The recent insider buying activity by Mesa Laboratories' CAO, along with other executive transactions, highlights ongoing interest in the company's stock. With a diverse product range and a global presence, Mesa Laboratories remains a key player in the technology sector. Investors often track such insider activities for potential insights, though it's important to remember that these actions do not necessarily predict future stock performance.